CLAIMS

1. A synthetic polynucleotide comprising the sequence of SEQ ID NO: 1.

2. The synthetic polynucleotide of claim 1 comprising a double stranded region, wherein the double stranded region comprises from 6 to 9 base pairs formed by the nucleotides at or near the 3’ and 5’termini.

3. The synthetic polynucleotide of claim 1, comprising at least one chemical modification, wherein the chemical modification is made to one of the group selected from the sugar, nucleobase or internucleoside linker of the synthetic polynucleotide.

4. The synthetic polynucleotide of claim 1, wherein each nucleotide comprises at least one chemical modification, wherein the chemical modification is made to one of the group selected from the sugar, nucleobase or internucleoside linker of the synthetic polynucleotide.

5. The synthetic polynucleotide of claim 3, wherein the modification is made to a sugar and the modification consists of a 2’ O-Methyl modification.

6. The synthetic polynucleotide of claim 3, further comprising a 3’ and/or 5’ terminal cap.

7. The synthetic polynucleotide of claim 6, wherein the 3’ and/or 5’ terminal cap is an inverted deoxythymidine, or an amino group (NH2).

8. The synthetic polynucleotide of claim 6, wherein the 3’ terminal cap comprises an inverted deoxythymidine and the 5’ terminal cap comprises an amino group (NH2).

9. The synthetic polynucleotide of claim 8 which is SEQ ID NO: 2.

10. The synthetic polynucleotide of claim 3, comprising a polyethylene glycol conjugate, wherein the polyethylene glycol conjugate is attached to the 5’ terminus, or the 3’ terminus, of the polynucleotide.

11. The synthetic polynucleotide of claim 10 which is SEQ ID NO: 3.

12. A complementary synthetic polynucleotide comprising the sequence of SEQ ID NO: 4.

13. The complementary synthetic polynucleotide of claim 12, wherein at least one nucleotide comprises a chemical modification.

14. The complementary synthetic polynucleotide of claim 12, wherein each of the nucleotides comprises at least one chemical modification.

15. The complementary synthetic polynucleotide of claim 13, wherein the at least one chemical modification is a 2'-O-methyl modification to a nucleotide sugar.

16. The complementary synthetic polynucleotide of claim 12, which comprises a 3' terminal cap.

17. The complementary synthetic polynucleotide of claim 16, wherein the 3' terminal cap is an inverted deoxythymidine.

18. The complementary synthetic polynucleotide of claim 12 which is SEQ ID NO: 5.

19. Use of a synthetic polynucleotide having a sequence selected from SEQ ID NOs. 1-3 or a complementary synthetic polynucleotide having a sequence selected from SEQ ID NO. 4-5, in the manufacture of a medicament for

(a) the treatment of a thrombotic disease, disorder or complication relating to Von Willebrand Factor (VWF);

(b) the treatment of a ventricular assist devices (VAD)-associated complication or disorder causing acquired Von Willebrand Syndrome;

(c) the treatment of an acquired Von Willebrand Syndrome complication or disorder associated with gastrointestinal (GI) bleeding associated with angiodysplasia;

(d) the treatment of thrombosis in the central nervous system caused by cerebral malaria, wherein the cerebral malaria is associated with elevated levels of VWF, VWF propeptide, and/or activated VWF;

(e) the treatment of gastrointestinal (GI) bleeding associated with Heyde's Syndrome due to loss of VWF multimers;

(f) restoring vessel patency in a subject having one or more vessel(s) occluded with at least one occlusive thrombus, wherein the vessel(s) are at least 50% occluded;

(g) disaggregating one or more occlusive thrombi in a subject having at least one vessel that is at least 50% occluded;

(h) preventing platelet aggregation in a subject having a thrombotic disorder or complication; or

(i) treatment of a complication or disorder comprises aberrant binding of VWF to erythrocytes.

20. The use according to (a) of claim 19, wherein the disease, disorder or complication relating to VWF is a thrombotic disorder, including ischemic stroke.

21. The use according to (b) of claim 19, wherein the VAD associated complication or disorder is selected from acquired Von Willebrand Syndrome (aVWS), angiodysplasia, occlusive thrombosis, and VAD-associated pump thrombosis.

22. The use according to (f) or (g) of claim 19, wherein the external layer of the occlusive thrombi is disaggregated.

23. The use according to (f) or (g) of claim 19, wherein the occlusive thrombi are formed under conditions of shear rates that are 10,000 s^{-1} or greater.

24. The use according to (f) or (g) of claim 19, wherein the occlusive thrombi are resistant to fibrinolysis and/or antithrombotic agents.

25. The use according to (f) or (g) of claim 19, wherein the subject has a condition selected from acute coronary syndrome, acute occlusion thrombosis, and ischemic stroke.

26. The use according to claim 19, wherein the synthetic polynucleotide is to be administered via intravenous injection, or subcutaneous injection.

27. The use according to claim 26, wherein the polynucleotide is to be administered via subcutaneous injection, wherein the bioavailability by subcutaneous injection is at least 85% relative to intravenous injection, and wherein the polynucleotide is to be administered at a dose of from 0.01 mg/kg to 0.5 mg/kg of the subject body weight.

28. The use according to claim 27, wherein the synthetic polynucleotide has a plasma half-life of from 70 hours to 100 hours.

29. The use according to claim 20, wherein the thrombotic disorder or complication is myocardial infarction, or ischemic stroke.